NovaBridge Biosciences develops drug candidates for cancer and eye disease, led by givastomig for gastric cancer. NBP reports earnings on Thu, Nov 12, 2026.
Earnings
Earnings calendar →Seasonality
How NBP has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in NBP in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NBP is in one of them and how their past NBP trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered NBP in an article yet. Here's the latest on the wider market.
About NovaBridge Biosciences
NovaBridge Biosciences is a biotechnology company based in Rockville, Maryland, that develops drug candidates for cancer and eye disease. Its lead program is givastomig, an antibody therapy being tested for gastric cancer and other tumors that express the CLDN18.2 protein. The company is also developing VIS-101, a candidate for wet macular degeneration and diabetic macular edema. Its treatments are aimed at patients worldwide.
- Headquarters
- Rockville, MD